Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021

May 2021 | 150 pages | ID: A7D445B59BEEN
DelveInsight

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight’s, “Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute respiratory distress syndrome (ARDS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute respiratory distress syndrome (ARDS) Understanding

Acute respiratory distress syndrome (ARDS): Overview

Acute respiratory distress syndrome (ARDS) is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of ARDS vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness. Along with medical history and physical examination, tests that help in diagnosis of ARDS are imaging tests, blood tests, and/or echocardiogram. Treatment options for ARDS include mechanical ventilation, fluid management, pharmacological treatment, extracorporeal lung support strategies, and other supportive measures. Gene therapy and stem cell therapy are under clinical investigation for the treatment of ARDS.

'Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute respiratory distress syndrome (ARDS) pipeline landscape is provided which includes the disease overview and Acute respiratory distress syndrome (ARDS) treatment guidelines. The assessment part of the report embraces, in depth Acute respiratory distress syndrome (ARDS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute respiratory distress syndrome (ARDS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute respiratory distress syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve Acute respiratory distress syndrome (ARDS).

Acute respiratory distress syndrome (ARDS) Emerging Drugs Chapters

This segment of the Acute respiratory distress syndrome (ARDS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute respiratory distress syndrome (ARDS) Emerging Drugs

• BIO-11006: BioMarck Pharmaceuticals

BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.

• MultiStem: Athersys

MultiStem is an 'off-the-shelf' stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and acute respiratory distress syndrome (ARDS). The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the acute respiratory distress syndrome (ARDS) program.

Further product details are provided in the report..

Acute respiratory distress syndrome (ARDS): Therapeutic Assessment

This segment of the report provides insights about the different Acute respiratory distress syndrome (ARDS) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acute respiratory distress syndrome (ARDS)

There are approx. 60+ key companies which are developing the therapies for Acute respiratory distress syndrome (ARDS). The companies which have their Acute respiratory distress syndrome (ARDS) drug candidates in the most advanced stage, i.e. Phase III include, Athersys.

• Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute respiratory distress syndrome (ARDS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute respiratory distress syndrome (ARDS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute respiratory distress syndrome (ARDS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute respiratory distress syndrome (ARDS) drugs.

Acute respiratory distress syndrome (ARDS) Report Insights

• Acute respiratory distress syndrome (ARDS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute respiratory distress syndrome (ARDS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute respiratory distress syndrome (ARDS) drugs?
• How many Acute respiratory distress syndrome (ARDS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute respiratory distress syndrome (ARDS)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute respiratory distress syndrome (ARDS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute respiratory distress syndrome (ARDS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Faron Pharmaceuticals
• BioMarck Pharmaceuticals
• Athersys
• Apeiron Biologics
• Cynata Therapeutics
• Orbsen Therapeutics
• GEn1E Lifesciences
• Exvastat
• Longeveron
• CohBar
• ZyVersa Therapeutics
• Abbreos
• Aviceda Therapeutics
• ImStem Biotechnology
• Bayer
• AVM Biotechnology
• Cartesian Therapeutics
• Sage Therapeutics
• Roivant Sciences
• ZyVersa Therapeutics
• Aerpio Pharmaceuticals
• Apeiron Biologics

Key Products

• Traumakine
• BIO-11006
• HLCM 051
• APN-01
• CYP 001
• Orbcel-C
• GEn1E-1124
• Imatinib
• Lomecel-B
• CB5064 analogs
• IC 100
• ABB-201
• IMS 001
• AVD-1010
• BAY 1097761
• AVM0703
• Descartes-30
• Brexanolone
• Gimsilumab
• IC 100
• Razuprotafib
• APN401

Contents

Introduction
Executive Summary
Acute respiratory distress syndrome (ARDS): Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Acute respiratory distress syndrome (ARDS) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Acute respiratory distress syndrome (ARDS) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute respiratory distress syndrome (ARDS) Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Traumakine: Faron Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
  Comparative Analysis
BIO-11006: BioMarck Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
  Comparative Analysis
GEn1E-1124: GEn1E Lifesciences
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
  Comparative Analysis
IC 100: ZyVersa Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Inactive Products
  Comparative Analysis
Acute respiratory distress syndrome (ARDS) Key Companies
Acute respiratory distress syndrome (ARDS) Key Products
Acute respiratory distress syndrome (ARDS)- Unmet Needs
Acute respiratory distress syndrome (ARDS)- Market Drivers and Barriers
Acute respiratory distress syndrome (ARDS)- Future Perspectives and Conclusion
Acute respiratory distress syndrome (ARDS) Analyst Views
Acute respiratory distress syndrome (ARDS) Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute respiratory distress syndrome (ARDS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Acute respiratory distress syndrome (ARDS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products